Remedy Robotics
Remedy Robotics builds the N1 System, an endovascular surgical robotics platform with custom catheters and AI-enabled software that lets clinicians perform stroke and cardiovascular interventions onsite, remotely, or autonomously. It targets hospitals and health systems worldwide via clinical trials and partnerships with stroke networks.
- Company typePrivate
- Founded2022
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Remedy Robotics does
Remedy Robotics is a San Francisco-based medical technology company developing the N1 System, an endovascular surgical robotics platform designed to perform neurointerventional and cardiovascular procedures with onsite, remote, or autonomous control. The system integrates proprietary custom-built catheters with AI-enabled software and machine-learning models that handle perception, planning, and control across the procedure — from femoral access through catheter navigation (e.g., to the M2 segment) to withdrawal — supporting independent control of up to five tools, contrast injection, and audiovisual communication, plus a remote Operator Console that lets clinicians drive the robot over standard internet connectivity. Founded in 2020–2022 by David Bell (CEO) and Jake Sganga (CTO), Remedy has progressed from first remote drive demonstrations (2021) through remote invivo animal work (Jan 2022), autonomous vascular-model navigation (Jan 2022), UCLA hospital integration (Dec 2023), first-in-human robotic neurointervention at Unity Health Toronto (Nov 2024), and the world's first fully remote human neurointerventional procedures (Oct 2025). The company targets hospitals and healthcare systems as enterprise customers, with planned FDA IDE submission, TGA approval in Australia, and a razor-and-blade-plus-software commercial model across N1 hardware, proprietary single-use catheters, and software/SaaS services.
Remedy Robotics firmographics
Firmographics- Name
- Remedy Robotics
- Legal name
- Remedy Robotics Inc.
- Website
- https://remedyrobotics.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Remedy Robotics builds the N1 System, an endovascular surgical robotics platform with custom catheters and AI-enabled software that lets clinicians perform stroke and cardiovascular interventions onsite, remotely, or autonomously. It targets hospitals and health systems worldwide via clinical trials and partnerships with stroke networks.
- Ownership category
- akta.pro rank
Remedy Robotics industry classification
Industry- Product category
- Endovascular Surgical Robotics
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
- akta.pro secondary industries
- Healthcare & Assistive Robotics (HDAAAIAC), Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)
Keywords
Where Remedy Robotics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Remedy Robotics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- N1 System (Robotic Hardware): Sale or lease of the Remedy N1 robotic system to hospitals and healthcare facilities. The system is currently under development and not yet approved for sale.
- Single-Use Catheters and Disposables: Consumable revenue from proprietary catheters used during procedures. The company has custom-built catheters as part of its proprietary hardware.
- Software/SaaS Services: Software-enabled services potentially including per-procedure fees, subscription models for remote control software, and AI-enabled planning and visualization tools.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels6 records
Remedy Robotics product offering
Product offeringCore offering
Remedy Robotics develops the N1 System, an endovascular surgical robot that performs entire thrombectomy and neurointerventional procedures with onsite, remote, or autonomous control. The platform combines custom-built catheters with AI-enabled software and machine learning, enabling clinicians to deliver endovascular intervention for stroke and cardiovascular emergencies without geographic barriers. The system is currently in clinical development and not yet commercially available.
Product overview
Remedy Robotics offers the N1 System - the world's first endovascular robot that performs entire procedures with onsite, remote, or autonomous control. The system combines proprietary custom-built catheters with AI-enabled software and machine learning to deliver flawless, immediate endovascular intervention for stroke and cardiovascular emergencies. The portfolio includes the core N1 robotic platform, custom-built catheters designed specifically for robotic procedures, and an Operator Console that enables clinicians to drive the robot remotely from anywhere. The system is under development and not yet available for sale.
Differentiator
Problem solved
Functional benefit
Products and services
- Remedy N1 System Endovascular surgical robot that performs entire procedures with onsite, remote, or autonomous control. Combines proprietary custom-built catheters with AI-enabled software and machine learning to deliver endovascular intervention for stroke and cardiovascular emergencies. Designed for hospitals and healthcare systems serving stroke and neurovascular patients, including those in geographic regions without local specialist interventionists.
- Remedy Custom-Built Catheters Proprietary single-use catheters custom-built for the N1 System, designed specifically for robotic endovascular procedures. Consumable component used per procedure and sold alongside the system to hospitals and healthcare facilities.
- Remedy Operator Console Surgical user interface through which clinicians drive the N1 System remotely. Enables operators to perform telerobotic endovascular interventions from any location with internet connectivity, including from a separate hospital than the patient.
Quantifiable outcome
- 97% of stroke patients across the world do not have access to life-saving endovascular thrombectomy
- +3 more outcomes
Companies that use Remedy Robotics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Remedy Robotics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Remedy Robotics partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- Mission ThrombectomycoreRemedy Robotics was chosen as the exclusive robotics partner by Mission Thrombectomy to expand access to thrombectomy treatment for stroke patients using Remedy's N1 System. The partnership aims to leverage telerobotic technology to improve global access to endovascular thrombectomy, especially in underserved regions. Mission Thrombectomy has been at the forefront of accelerating access to endovascular thrombectomy since 2016, with regional committees in over 100 countries.
- Australian Stroke AlliancecoreStrategic partnership with the Australian Stroke Alliance (representing 40 different health bodies) to expand access to endovascular thrombectomy in Australia. Remedy will collaborate with the alliance to gain regulatory approval and deploy its remotely operated robotic system across hospitals to improve stroke care, especially in rural and remote areas. The partnership aims to conduct remote stroke treatment trials in Darwin and Alice Springs.
- UCLA (University of California, Los Angeles)coreHospital integration and connectivity study conducted at UCLA, with results published in the American Journal of Neuroradiology. The study demonstrated successful integration of the robot into a clinical environment with remote operation by clinicians from multiple locations up to 2,700 miles away.
- Unity Health TorontocoreClinical partnership with Unity Health Toronto for first-in-human procedures (November-December 2024) and world's first fully remote neurointerventional procedures (October 2025). Dr. Vitor Mendes Pereira and team at Unity Health performed the landmark procedures. The remote procedures were conducted with the surgeon at St. Joseph's Health Centre and patients at St. Michael's Hospital across Toronto.
- Covance (San Mateo)minorFirst invivo (living) trials completed in January 2022 with expert guidance of the team at Covance in San Mateo. The trial involved swine whose neurovasculature is similar to humans, with simulated procedures completed without damage to vasculature.
- Society of Vascular and Interventional Neurology (SVIN)corePartnership with SVIN through Mission Thrombectomy, which is an initiative of SVIN. The broader SVIN network will provide critical input and support for N1 System development. Remedy attended SVIN 2025 Annual Meeting in Orlando.
- Mass General BrighamminorListed as a hospital partner on the Remedy Robotics website, indicating collaboration or clinical interest in the technology.
- Barts Health NHSminorListed as a hospital partner on the Remedy Robotics website.
- Monash University / Monash HealthminorListed as a hospital and academic partner on the Remedy Robotics website.
- Royal Melbourne HospitalminorListed as a hospital partner on the Remedy Robotics website.
- Austin HealthminorListed as a hospital partner on the Remedy Robotics website.
- National University Hospital Singapore (NUHS)minorListed as a hospital partner on the Remedy Robotics website.
- National University Hospital Sri LankaminorListed as a hospital partner on the Remedy Robotics website.
- Gold Coast University HospitalminorListed as a hospital partner on the Remedy Robotics website.
- Jikei University HospitalminorListed as a hospital partner on the Remedy Robotics website.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Remedy Robotics competitors and assessment
Company assessmentEmerging players
- Vicarious Surgical: Public surgical robotics company building a single-port robotic system for abdominal procedures. Different indication but comparable business-model risks: pre-revenue, capital-intensive, chasing surgical-robotics adoption in a hospital procurement environment.
- Robocath: French startup developing the R-One robotic platform for coronary and peripheral endovascular interventions. Direct endovascular robotics competitor with overlapping procedural use cases (cardiovascular intervention) but earlier commercial stage and narrower indication focus.
- Brainlab: Brainlab sells surgical navigation and intra-operative imaging used by neurointerventionalists, overlapping with Remedy's hospital customers. Could partner with or compete against Remedy in the neurointerventional workflow.
- Capstan Medical: Early-stage company developing a catheter-based robotic platform for structural heart and endovascular procedures. Closest emerging-startup analog to Remedy in technology approach and clinical focus on catheter-delivered therapy.
Broad incumbents
- MicroPort: MicroPort has endovascular and neurovascular device franchises (e.g., APOLLO, WILLIS covered stents) overlapping with Remedy's stroke-treatment customer base. Could add a robotics platform through acquisition or internal development.
- Intuitive Surgical: Dominant surgical robotics incumbent (da Vinci) with the Ion platform for catheter-based procedures. Sets the benchmark for hospital robotics adoption and could expand Ion into neurointerventional indications, applying vastly greater resources against Remedy's niche.
- Johnson & Johnson (MedTech Robotics): J&J's Ottava general surgery robot and MONARCH platform for bronchoscopy make it a broad surgical robotics incumbent. Has the resources, regulatory expertise, and global hospital salesforce to enter neurointerventional robotics as the market matures.
- Medtronic: Medtronic operates in both endovascular intervention (Solitaire stent retriever, cranial robotics) and surgical robotics (Hugo platform). Has the capital, clinical trial infrastructure, and hospital relationships to enter telerobotic neurointervention if the market validates.
- Stryker: Stryker's Neurovascular division dominates mechanical thrombectomy (Trevo devices) and owns Mako surgical robotics. Strong incumbent in both Remedy's adjacent neurovascular device market and the broader surgical robotics space, with far greater capital and distribution.
Direct peers
- Penumbra: Penumbra's REAL System is the most direct endovascular robotic competitor — also targeting mechanical thrombectomy with a joystick-controlled robot. Closely aligned business model (capital equipment + consumables) and customer base (neurointerventional radiologists and stroke centers).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Remedy Robotics social profiles
Digital presenceRemedy Robotics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Remedy Robotics leadership team
Management profileNumber of profiles
Profiles4 records
Remedy Robotics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Remedy Robotics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Remedy Robotics
What does Remedy Robotics do?
Remedy Robotics develops the N1 System, an endovascular surgical robot that performs entire thrombectomy and neurointerventional procedures with onsite, remote, or autonomous control. The platform combines custom-built catheters with AI-enabled software and machine learning, enabling clinicians to deliver endovascular intervention for stroke and cardiovascular emergencies without geographic barriers. The system is currently in clinical development and not yet commercially available.
Is Remedy Robotics a public or private company?
Remedy Robotics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Remedy Robotics founded?
Remedy Robotics was founded in 2022. It employs 11 to 50 people.
Where is Remedy Robotics based?
Remedy Robotics is headquartered in San Francisco, United States, in the North America region.
How does Remedy Robotics make money?
Three revenue lines are on record. N1 System (Robotic Hardware) is the primary driver. The others are single-Use Catheters and Disposables and software/SaaS Services.
Who are Remedy Robotics's main competitors?
Emerging players on record are Vicarious Surgical, Robocath, Brainlab and Capstan Medical. Broad incumbents are MicroPort, Intuitive Surgical, Johnson & Johnson (MedTech Robotics), Medtronic and Stryker. Penumbra is listed as a direct peer.
Does Remedy Robotics have an API?
No public API is recorded for Remedy Robotics.
What industry is Remedy Robotics in?
Remedy Robotics's product category is Endovascular Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HDAAAIAC, Healthcare & Assistive Robotics. Its NAICS code is 339112 and its SIC code is 3841.